Verition Fund Management LLC Buys Shares of 40,714 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Verition Fund Management LLC purchased a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Rating) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 40,714 shares of the company’s stock, valued at approximately $1,879,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. HighTower Advisors LLC grew its holdings in shares of Zentalis Pharmaceuticals by 1.2% in the 4th quarter. HighTower Advisors LLC now owns 30,262 shares of the company’s stock valued at $2,544,000 after buying an additional 357 shares during the period. Captrust Financial Advisors grew its holdings in shares of Zentalis Pharmaceuticals by 15,160.0% in the 1st quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after buying an additional 758 shares during the period. Rhumbline Advisers grew its holdings in shares of Zentalis Pharmaceuticals by 2.3% in the 4th quarter. Rhumbline Advisers now owns 35,448 shares of the company’s stock valued at $2,980,000 after buying an additional 782 shares during the period. Teacher Retirement System of Texas grew its holdings in shares of Zentalis Pharmaceuticals by 32.5% in the 4th quarter. Teacher Retirement System of Texas now owns 4,323 shares of the company’s stock valued at $363,000 after buying an additional 1,061 shares during the period. Finally, Advisor Group Holdings Inc. grew its holdings in shares of Zentalis Pharmaceuticals by 1,082.5% in the 4th quarter. Advisor Group Holdings Inc. now owns 1,218 shares of the company’s stock valued at $102,000 after buying an additional 1,115 shares during the period.

Insider Buying and Selling

In related news, COO Kevin D. Bunker sold 1,710 shares of the stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $30.02, for a total transaction of $51,334.20. Following the sale, the chief operating officer now owns 108,290 shares in the company, valued at approximately $3,250,865.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 12,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $25.26, for a total value of $315,750.00. Following the sale, the president now owns 454,385 shares in the company, valued at $11,477,765.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Kevin D. Bunker sold 1,710 shares of the firm’s stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $30.02, for a total transaction of $51,334.20. Following the completion of the sale, the chief operating officer now owns 108,290 shares in the company, valued at approximately $3,250,865.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 44,210 shares of company stock worth $1,268,834. Corporate insiders own 19.90% of the company’s stock.

Zentalis Pharmaceuticals Stock Down 6.0 %

Shares of NASDAQ:ZNTL opened at $23.86 on Monday. The company’s 50 day moving average price is $28.21 and its two-hundred day moving average price is $30.18. Zentalis Pharmaceuticals, Inc. has a 12-month low of $17.33 and a 12-month high of $87.19. The firm has a market cap of $1.36 billion, a PE ratio of -6.20 and a beta of 1.88.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Rating) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by ($0.13). On average, research analysts expect that Zentalis Pharmaceuticals, Inc. will post -4.78 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. SVB Leerink reduced their target price on shares of Zentalis Pharmaceuticals from $67.00 to $42.00 and set an “outperform” rating for the company in a research note on Wednesday, August 10th. HC Wainwright reduced their price objective on shares of Zentalis Pharmaceuticals from $120.00 to $55.00 and set a “buy” rating for the company in a research note on Wednesday, August 10th. Cowen initiated coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, July 12th. They issued an “outperform” rating on the stock. Morgan Stanley lowered their price target on shares of Zentalis Pharmaceuticals from $95.00 to $60.00 and set an “overweight” rating on the stock in a report on Thursday, August 11th. Finally, Cowen initiated coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, July 12th. They issued an “outperform” rating on the stock. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $61.38.

Zentalis Pharmaceuticals Company Profile

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.

See Also

Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Rating).

Institutional Ownership by Quarter for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.